论文部分内容阅读
由Shire公司研制的lifitegrast滴眼剂于2016年7月11日经美国FDA批准上市,用于治疗成人干眼症,其商品名为Xiidra。该药是目前唯一用于改善干眼病症状的处方滴眼剂~([1])。Lifitegrast的中文化学名称:(S)-2-[2-(苯并呋喃-6-羰基)-5,7-二氯-1,2,3,4-四氢异喹啉-6-甲酰胺基]-3-(3-甲磺酰基苯基)丙酸;英文化学名称:(S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid;
Lifitegrast Eye Drops, developed by Shire Inc., was approved by the U.S. FDA on July 11, 2016 for the treatment of adult eye dryness under the trade name Xiidra. This medicine is the only prescription eye drop for improving dry eye symptoms (1). Chinese chemical name of Lifitegrast: (S) -2- [2- (Benzofuran-6-carbonyl) -5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamide (S) -2- (2- (2- (benzofuran-6-carbonyl) -5,7-dichloro- 4-tetrahydroisoquinoline-6-carboxamido) -3- (3- (methylsulfonyl) phenyl) propanoic acid;